Pharma business
Sandoz spin-off could open door to new litigation against Novartis
Novartis has announced it is to divest its generics division Sandoz. The subsidiary, which runs the business of biosimilars and off-patent drugs, will become entirely independent, creating one of Euro
...
13 September 2022 by Joshua Silverwood
